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Abstract
Background: Pulmonary arterial hypertension (PAH) is a severe disease. 6-minute walk distance (6MWD) is correlated 
with the prognosis of  PAH patients. We previously reported the safety and efficacy of  pulmonary artery denervation 
(PADN) for patients with idiopathic PAH (IPAH) who were unresponsive to target drugs. However, PADN has not been 
tested in a well-designed study for patients with IPAH/PAH or pulmonary hypertension (PH).
Objectives: The present study aimed to analyze the difference in 6-minute walk distance (6MWD) at 6-month after 
PADN and standard pharmacotherapy.
Methods: Between February 2013 and June 2014, a total of  28 patients with IPAH (n=11), PH from left heart disease 
(n=8), and 9 secondary PAH were included in this study. A wash-out consisting of  5 half-lives for target drugs was per-
formed for all the patients. Next, medications were prescribed for a 6-month duration for the patients (Medication treat-
ment). A second wash-out (5 half-lives) was completed for all the patients after the 6-month medication treatment. Finally, 
PADN was performed for these patients (PADN treatment), and an additional 6-month follow-up period was completed. 
The primary endpoint was the difference in the ∆6MWD (defined as value at 6-month minus baseline) between two treat-
ments. 
Results: After 6-month treatment, there was significant difference in the ∆6MWD between PADN (65±85 m) and 
Medication (13±24 m) treatment (95% CI -21.34-3.49, p=0.002), coupling with the differences in the reduction of  systolic 
pulmonary artery pressure (PAP, -13.75±14.1 mmHg vs. -0.46±3.47 mmHg, p<0.001), mean PAP (-7.86±6.10 mmHg vs. 
-0.14±2.48 mmHg, p<0.001), mean right atrial pressure (-2.53±3.75 mmHg vs. -0.21±2.62 mmHg, p=0.007), and pulmo-
nary vessel resistance (-4.59±7.06 Woods unit vs. -0.17±2.56 Woods unit, p=0.001). PADN treatment was associated with 
less frequent 6-month PAH-related event (10.8%), compared to 42.9% in Medication treatment (p=0.005).
Conclusion: The present study showed that PADN treatment was associated with significant improvement of  6MWD 
and less PAH-related event. Further study was required to show the benefit of  PADN in reducing mortality in patients 
with IPAH and secondary PAH.
Keywords: Pulmonary Arterial Hypertension; Pulmonary Artery Denervation; 6-Minute Walk Distance; Controlled Be-
fore and After Study.
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Introduction
Pulmonary arterial hypertension (PAH) is a severe disease char-
acterized by progressive right ventricular (RV) failure resulting in 
premature death [1]. Based on the WHO classification, PAH is 
classified into 5 groups [1, 2] based on the different mechanisms 
and etiologies involved in the development of  PAH. Target drugs 
included endothelin receptor antagonists, prostacyclin, and phos-
phodiesterase type 5 inhibitors (5’-PDE), which have all been ex-
tensively used and confirmed to be effective and safe for PAH 
patients [1, 2]. Nevertheless, there is tremendous controversy 
regarding the long-term benefits and cost-effectiveness of  these 
drugs [3]. The main reason is that the pathologic mechanisms of  
PAH is still under clear. 
Over-activation of  sympathetic nerves activity has been proposed 
to participate in the development of  PAH [4], but medication us-
ing non-selective β-blockers did not show any improvement of  
PAH [5]. Based on the earlier report by Jurastch et al., [6] that pul-
monary arterial (PA) sympathetic nerves ending localized around 
the distal PA bifurcation area and that surgical denervation of  
these nerves was associated with significant reduction of  pulmo-
nary arterial pressure (PAP), our group performed an actual ex-
perimental study and found that percutaneous pulmonary artery 
denervation (PADN) could completely abolish the increase of  
pulmonary arterial pressure (PAP) induced by an inflated balloon 
at proximal left interloba artery, the finding confirmed that PA 
sympathetic nerves might localize proximally [7]. Consequently, 
we designed our first-in-man “PADN-1 study” and results showed 
the benefits of  PADN for idiopathic PAH (IPAH) patients who 
were unresponsive to target drugs [8]. However, the uncontrolled 
feature of  the PADN-1 study [8] raised global interests and con-
cerns regarding its safety and efficacy [9]. As a result, we designed 
this controlled PADN-2 study in an attempt to elucidate the im-
provements in a 6-minute walk distance (6MWD), as well as the 
hemodynamic and clinical outcomes after the PADN procedure 
in patients with PAH due to variety of  underlying etiologies.
Methods
Patient Population
This study was conducted at two centers. Patients with a resting 
mean PAP (mPAP) ≥ 25 mmHg with WHO functional class II-
IV PAH were included. For patients with pulmonary hyperten-
sion (PH) induced by LHD, additional requirements included a 
PVR >2.5 woods unit and a pulmonary arterial obstructive pres-
sure (PAOP) > 15 mmHg at rest. Patients who had active inflam-
mation and cancer were excluded. Patients with PAH secondary 
from portable hypertension and drug or toxin exposure were also 
excluded. The study protocol was approved by the Institute Re-
search Board (Nanjing Medical University) and informal written 
consent was obtained from all the patients.
Study Design
The present study was designed as a controlled before and after 
study (Figure 1). All patients who met the inclusion and exclusion 
criteria were included and entered into the first wash-out period 
(defined as stopping all medications for at least 5 half-lives, with 
the exception of  warfarin) as right heart catheterization and aden-
osine test for all patients were not performed before the study. If  
the patients were taking multiple drugs, the longest half-lives of  
the drug was selected. For example, for a patient who was taking 
bosentan (half-time <5 h) and digoxin (half-time=33h), the wash-
out period would be 5 x 33 h=165 h (7 days). After the wash-
28 patients with IAPH/PAH/PH
RHC, cardiac echo
STOP target drugs for 5 half-lives
Standard pharmacotherapy, 6-month follow-up
RHC, cardiac echo, clinical follow-up
Pulmonary artery denervation (PADN)
RHC, cardiac echo, 6-month clinical follow-up
RHC, cardiac echo, 12-month clinical follow-up
STOP target drugs for 5 half-lives
∆6MWD
∆6MWD
Comparison
Figure 1. Study FlowChart
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out period, the drugs were prescribed again and continued for 6 
months (Medication treatment). The selection of  drugs was left 
to the physician’s discretion based on their comprehensive analy-
sis. After 6 months, the patients underwent a second wash-out 
period of  5 half-lives in order to establish PADN as a standard 
alone therapy; next, PADN was performed, followed by 6-month 
and 12-month clinical follow-up (PADN treatment). 
Medication 
Immediately after the grouping, warfarin was continuously pre-
scribed. Otherwise, aspirin (100 mg/d) and Plavix (75 mg/d) were 
prescribed instead of  warfarin for patients who could not tolerate 
warfarin. Immediately after the PADN procedure, the standard 
medication for PAH were stopped for all the patients, and this 
was evaluated by the physician based on the patients’ symptoms. 
Assessment of  Functional Capacity
Baseline blood samples were obtained for the analysis of  N-ter-
minal brain natriuretic peptide (NT-pro BNP) levels prior to the 
exercise test. The 6MWD [8] according to standard methods, the 
Borg scale and the WHO functional class [1] at rest and during 
exercise were estimated and recorded by one physician who was 
blinded to the study design. 
Echocardiographic Measurements
All echocardiograms were performed (Vivid 7, General Electric 
Co., Easton Turnpike, CT, US) and interpreted in the Nanjing 
Echocardiographic Laboratory using the American Society of  
Echocardiography recommendations [10]. Digital echocardio-
graphic data that contained a minimum of  3 consecutive beats (or 
5 beats in cases of  atrial fibrillation) were acquired and recorded. 
RV systolic pressure (sRVP) is equal to systolic PAP (sPAP) in the 
absence of  pulmonary stenosis. sPAP is equal to the sum of  right 
atrial (RA) pressure (RAP) and the RV to RA pressure gradient 
during systole. RAP was estimated based on the echocardiograph-
ic features of  the inferior vena cava and was assigned a standard 
value [11]. The RV to RA pressure gradient was calculated as 4vt
2 
using the modified Bernoulli equation in which vt is the velocity 
of  the tricuspid regurgitation jet in m/s. mPAP was estimated ac-
cording to the velocity of  the pulmonary regurgitation jet in m/s. 
The tricuspid excursion index (Tei) [12] is defined as (A – B)/B in 
which A is the time interval between the end and the onset of  tri-
cuspid annular diastolic velocity, and B is the duration of  tricuspid 
annular systolic velocity (or the RV ejection time).
Right Heart Catheterization
A 7F flow-directed Swan-Ganz catheter (Edwards, USA) was in-
serted percutaneously into the internal jugular vein for the meas-
urements of  the resting RAP, sRVP, sPAP, mPAP, PAOP, and car-
diac output (CO) values. The PVR [= (mPAP-PAOP)/CO] was 
then calculated. All the measurements were performed at the end 
of  expiration. If  the PAOP measurement was unreliable, the left 
ventricular end-diastolic pressure was measured and used rather 
than the PAOP measurement. Two blood samples from the RA, 
RV and PA were obtained for the measurements of  oxygen pres-
sure and saturation. If  the difference between the oxygen pres-
sure or saturation measurement of  these two samples was >7%, 
further sampling was performed to identify the location of  the 
left-to-right shunt.
PADN Procedure
PADN was performed at three sites (A, B and C) at the conjunc-
tional area between the distal main trunk and the ostial left branch 
(Figure 2). The following ablation parameters were programmed 
at each point: a temperature of  45°C-50°C, energy ≤15 W, and a 
time of  120 seconds. The procedure would cease for 10 seconds 
if  the patient felt intolerable chest pain during the procedure. The 
EKG and pressure lines (including cardiac output) were moni-
tored and continuously recorded throughout the procedure.
 
The success of  a PADN procedure was defined as a reduction of  
sPAP or mPAP immediately after the procedure, or at 24 hours 
with a ≥10% compared to the baseline values, without intra-pro-
cedural complications. 
Study Endpoints
The primary endpoint was the difference in 6MWD after the 
6-month between the medication and PADN treatment. The sec-
Figure 2. (I) anterior-posterior and cranial (20°) view of  pulmonary arterial angiograph.
(II) red line represents the lateral wall of  MPA, blue for anterior wall of  LPA, the crossing site by these two lines is the point 
A; the crossing site by yellow line (reflects the posterior wall of  LPA) and red line is the point B which is 1-2 mm posteriori 
to the point A; green line starts from the inferior wall of  RPA and ends at the point A, the point C localizes at this level and 
1-2 mm anteriorly to the point A
(III) a PADN catheter with 10 electrodes is positioned at the distal MPA, electrodes A, B and C match with the points A, 
Band C.
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ondary endpoints included composite and individual PAH-related 
events, including the worsening of  PAH, the initiation of  treat-
ment with the intravenous or subcutaneous injection of  drugs, 
lung transplantation, atrial septostomy or all-cause death. Repeat 
hospitalization also served as a secondary endpoint.
Follow-Up
The patients were monitored in the CCU for at least 24 h. All 
measurements were repeated post-procedure, at 24 h, at 3-month, 
at 6-month, and at 12-month. CT scanning of  the pulmonary 
artery were performed before and at 6-month after the PADN 
procedure.
Definition and Outcome Measures
The worsening of  PAH was defined as the occurrence of  all 
three of  the following measurements: a decrease in the 6MWD 
of  at least 15% from baseline, confirmed by a second 6MWD 
performed on a different day within 14 days of  the first measure-
ment; a worsening of  the symptoms of  PAH; and the need for 
additional treatment for PAH. A worsening of  the symptoms of  
PAH was defined as any of  the following measurements: a change 
from baseline to a higher WHO functional class (or no change in 
patients who were in WHO functional class IV at baseline) and 
the appearance or worsening of  signs of  right heart failure, which 
did not respond to oral diuretic therapy. An independent clinical 
event committee adjudicated, in a blind fashion, all the events re-
lated to PAH and all the deaths that were reported up to the end 
of  the treatment.
Statistical Analysis
All the analyses were performed using the statistical program 
SPSS 19.0 (SPSS Institute Inc., Chicago, IL., USA). Statistical 
significance was defined as a two-sided P value <0.05. Based on 
our previous data, the Δ6MWD (defined as the 6MWD at the 
6-month follow-up minus the baseline 6MWD) was approximate-
ly +60 m after PADN treatment and +15 m after the medication 
treatment. A total of  28 patients were required to achieve signifi-
cance (2-sided p-value, 80% power) between the two arms. The 
difference in each variable (at the 6-month period minus the base-
line) for each treatment was calculated and compared between the 
two treatments. The continuous variables were expressed as the 
mean ± SD. A normality test for all the continuous variables was 
performed using the Kolmogorov–Smirnov and Shapiro–Wilk 
tests. The differences in the continuous variables between the 
two treatments were analyzed using a paired t-test or the Mann-
Whitney U test when appropriate. The categorical variables were 
compared using Fisher's exact test. The event-free survival rate 
was generated using the Kaplan-Meier method and was analyzed 
with the log-rank test.
Results
Baseline Patient Characteristics
Between March 2013 and June 2013, a total of  28 patients (11 
males and 17 females, with an average age of  49 years) were 
enrolled in the current study. Within this cohort, there were 8 
patients with idiopathic PAH (IPAH), 9 patients with pulmonary 
hypertension (PH) induced by left heart dysfunction (LHD), and 
11 PAHs secondary to CTD (n=4, connective tissue disease), 
chronic thromboemboli (n=3, CTE) and congenital heart disease 
after surgical repair (n=4, CHDSR, Table 1), respectively. The 
mean time interval from the diagnosis of  PAH to the present 
study was 4.24 years. At enrollment, most of  the patients were put 
on diuretics and prostacyclins; an endothelin receptor antagonist 
was prescribed for 5 IPAH patients, and all the LHD patients 
received a beta-blocker treatment.
Medical Treatment
After the first wash-out for 5 half-lives, 21.4% of  patients were 
put on prostacyclin, and an endothelin receptor antagonist was 
prescribed to 35.8% of  patients (Table 1). During the second 
wash-out, there was 1 patient with previous myocardial infarction 
who is medically dependent on diuretics and this was prescribed 
immediately.
Improvement of  6MWD Between Treatments
At 6-month, the NT-pro BNP and WHO functional class 
decreased significantly after both treatments (Table 2). Notably, 
the 6MWD increased from 361±112 m to 373±111 m in the 
Medication treatment (p=0.009) and from 358±115 m to 423±98 
m in the PADN treatment (p<0.001). The 6MWD after PADN 
treatment, but neither before any treatment nor after medication, 
was negatively correlated with mPAP (r=-0.416, p=0.028) and 
sPAP (r=-0.401, p=0.034, Figure 3A), and WHO functional class 
(r=-0.710, p<0.001) and PVR (r=-0.380, p=0.046).
The Δ6MWD was +13±24 m (+3.9% increase) 6-month after 
Medication treatment, which was significantly different to the 
65±85 m measurement (+23.9% increase, 95% CI: -21.34~-
3.49, p=0.002, Table 3) 6-month after PADN treatment. After 
Medication treatment, there were 9 patients (32%) whose 6MWD 
decreased (range from -6m to -47m). Of  those 9 patients, 5 
patients had an average 6MWD increase of  45 m 6 months after 
the PADN treatment, whereas no change was observed in 4 
patients. When follow-up was extended to one-year, there were 2 
patients (7%) after the PADN procedures who had no changes in 
6MWD. At one-year after PADN procedure, the average Δ6MWD 
was 92 m (Figure 3B).
Comparison of  the Differences in Hemodynamic Between 
the Two Treatments
The Δ sPAP, Δ mPAP, Δ sRVP and Δ mean RAP values 
measured by either cardiac echo or right heart catheterization 
at 6-month after PADN treatment were greater than those at 
6-month after Medication treatment (all p<0.05, Table 3), with 
resultant significant differences in the increase of  cardiac output 
(+0.67±1.05 L/min/1.73m2 vs. +0.06±0.24 L/min/1.73m2, 
95% CI: -0.10~-0.20, p=0.005), reduction of  the pericardial 
fluid amount (-0.74±2.63 mm vs. +0.11±0.93 mm, 95% CI: 
-1.04~2.47, p=0.036) and Tei (-0.34±0.11 points vs. -0.04±0.09 
points, 95% CI: 0.24~0.35, p<0.001). At one-year after PADN 
treatment, there was a gradual reduction of  either mPAP or PVR 
(Figure 3C). 
All the measurements were non-significant different between 
patients with secondary PH from left heart disease and patients 
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Table 1. Baseline Characteristics and Medical Treatment.
Variables Results
Patient number, n 28
Male, n (%) 11 (39.3)
Age, yr 49±17
Etiology, n (%)
IPAH 11 (39.3)
LHD 8 (28.6)
CTD 2 (7.1)
CTEPH 3 (10.7)
CHDSR 4 (14.3)
Time from diagnosis of  PAH to screening, yr 4.24 ±7.13
Chest pain 8 (28.6)
Syncope 4 (14.3)
Fatigue 27 (96.4)
Dyspnea 27 (96.4)
Medication, n (%) at screening
Diuretics 23 (82.1)
Calcium-channel antagonist 4 (14.3)
Beta-blocker 8 (28.6)
Prostacyclin 23 (82.1)
5'-PDE 10 (35.7)
ET receptor antagonist 5 (17.9)
Digoxin 13 (46.4)
Medication treatment*
Diuretics 22(78.6)
Calcium-channel antagonist 7(25.0)
Beta-blocker 8(28.6)
Prostacyclin 6(21.4)
5’PDE 11(39.3)
ET receptor antagonist 10(35.8)
Digoxin 10(35.7)
*indicated the medication started immediately after first wash-out
IPAH: Idiopathic Pulmonary Hypertension; LHD: Left Heart Disease; CTD: Connective Tissue Disease; CTEPH: Chronic Thrombolyticpulmonary Hypertension; CHDSR: Congenital 
Heart Disease After Surgical Repair; 5’-PDE: Phosphodiesterase Type 5 Inhibitor.
Table 2. Comparison of  Measurements Between Medication and PADN Treatment.
Medication (n=28) PADN (n=28)
Prior-to 6-month p Prior-to 6-month p
NT-pro BNP, pg/ml 2293±2741 1732±1878 0.007 2669±3178 1296±947 0.015
WHO class, point 2.75±0.52 2.46±0.58 0.009 2.75±0.52 2.21±0.63 <0.001
6MWD, mm 361±112 373±111 0.009 358±115 423±98 <0.001
Cardiac output, L/min 3.2±0.94 3.26±0.89 0.221 3.25±1.05 3.91±1.08 0.002
RHC
sPAP, mmHg 91.9±33.0 91.5±33.4 0.485 91.9±33.3 78.2±29.4 <0.001
mPAP, mmHg 56.1±21.1 55.9±21.2 0.762 56.7±21.8 48.9±19.2 <0.001
PCWP, mmHg 13±7.7 13.8±6.9 0.365 12.5±8.6 12.9±6.3 0.788
mRAP, mmHg 11.5±4.2 11.8±4.6 0.442 11.4±4.7 8.8±3.4 0.001
sRVP, mmHg 89.3±31.2 91.3±32.1 0.255 89.3±31.6 83.0±34.7 0.147
PVR, woods unit 13.8±7.6 13.6±6.9 0.721 14.3±8.6 9.7±6.8 0.002
Cardiac echo
mPAP, mmHg 47.9±24.2 45.6±23.2 <0.001 47.4±24.8 38.1±16.5 0.002
mRAP, mmHg 11.8±3.1 11.1±2.8 0.043 11.8±3.1 8.9±3.1 <0.001
sRVP, mmHg 96.0±87.9 87.9±26.9 <0.001 96.1±31.7 78.6±23.3 <0.001
sPAP, mmHg 98.1±29.5 87.2±25.2 <0.001 98.2±32.2 79.9±24.6 <0.001
Pericardial fluid, mm 1.11±1.64 1.43±1.93 0.059 1.96±2.89 0.85±0.89 0.002
RV Tei, % 0.59±0.17 0.55±0.16 0.029 0.69±0.09 0.36±0.09 <0.001
PADN: Pulmonary Artery Denervation; NT-pro BNP: N Terminal-Pro Brain Natriuretic Peptide; 6MWD: 6-Minute Walk Distance; RHC: Right Heart Catheterization; 
sPAP: Systolic Pulmonary Arterial Pressure; mPAP: Mean Pulmonary Arterial Pressure; mRAP: Mean Right Atrial Pressure; sRVP: Systolic Right Ventricular (RV)Pres-
sure; PVR: Pulmonary Vessel Resistance.
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Table 3. Comparison of  the Differences of  Measurements After the 6-Month Treatment Between the Medication and 
PADN Treatment
Medication PADN 95% CI p
NT-pro BNP, pg/ml -562±1009 -1373±2792 -42.84~1665.44 0.062
WHO functional 
class,point
-0.36±0.49 -0.54±0.58 -0.10~0.46 0.202
6MWD, m 13±24 65±85 -21.34~-3.49 0.002
% of  increase 3.9% 23.9% -0.31~-0.09 0.001
Cardiac output, L/min 0.06±0.24 0.67±1.05 -0.10~-0.20 0.005
RHC
sPAP, mmHg -0.46±3.47 -13.75±14.1 8.38~18.19 <0.001
mPAP, mmHg -0.14±2.48 -7.86±6.10 5.26~10.18 <0.001
PCWP, mmHg 0.82±4.72 0.36±6.96 -1.63~2.56 0.653
mRAP, mmHg -0.21±2.62 -2.53±3.75 0.70~3.93 0.007
sRVP, mmHg 1.96±8.93 -6.22±22.07 1.76~14.62 0.014
PVR, woods unit -0.17±2.56 -4.59±7.06 1.99~6.83 0.001
Cardiac echo
mPAP, mmHg -2.36±2.78 -9.28±13.93 1.98~11.86 0.008
mRAP, mmHg -0.54±1.57 -2.86±2.86 1.20~3.44 <0.001
sRVP, mmHg -8.07±9.73 -17.54±16.97 4.78~14.15 <0.001
sPAP, mmHg -10.89±11.87 -18.25±16.73 3.13~11.58 0.001
Pericardial fluid, mm 0.11±0.93 -0.74±2.63 -1.04~2.47 0.036
RV Tei, % -0.04±0.09 -0.34±0.11 0.24~0.35 <0.001
PADN: Pulmonary Artery Denervation; NT-pro BNP: N Terminal-Pro Brain Natriuretic Peptide; 6MWD: 6-Minute Walk Distance; 
RHC: Right Heart Catheterization; sPAP: Systolic Pulmonary Arterial Pressure; mPAP: Mean Pulmonary Arterial Pressure; mRAP: 
Mean Right Atrial Pressure; sRVP: systolic Right Ventricular (RV)Pressure; PVR: Pulmonary Vessel Resistance
Figure 3A. Systolic pulmonary arterial pressure (sPAP, p=0.034) and mean pulmonary arterial pressure (mPAP, p=0.028) after 6-month 
treatment were negatively correlated with with 6-minute walk distance.
Figure 3B. Dynamic change of  6-minute walk distance (6MWD). The average increment of  6MWD at 6-month and 12-month after PADN 
treatment was 65 m and 93 m, respectively, it was 12 m after the 6-month medication. 
Figure 3C. Gradual reduction of  mean pulmonary arterial pressure (mPAP) and pulmonary vessel resistance (PVR) prior-to, 6-month 
after medication, and after pulmonary artery denervation (PADN).
0
50
100
150
200
250
300
350
400
450
6-
 m
in
ut
e 
w
alk
 d
ist
an
ce
 (m
)
Baseline Medication 1-m 3-m 6-m 12-m
Month after PADN procedure
B
200.00 300.00 400.00 500.00 600.00 700.00
6- minute walk distance (m)
.00
25.00
50.00
75.00
100.00
125.00
Pu
lm
on
ar
y 
ar
te
ria
l p
re
ss
ur
e 
(m
m
H
g) A
6-month mPAP, r=0.416, p=0.028
6-month sPAP, r=0.401, p=0.034
0
10
20
30
40
50
60
mPAP (mm Hg)
PVR (Wood Unit)
Baseline Medication Post-PADN 24h 3-month 6-month 12-month
Figure 3.
C
Chen SL, Zhang H, Xie DJ, Zhang FF, Zhou L, et al., (2016) Pulmonary Artery Denervation for Treatment of  Pulmonary Arterial Hypertension: Results From a Controlled Before 
and After Study. Int J Cardiol Res. 3(2), 68-77.
74
   OPEN ACCESS                                                                                                                                                                              http://scidoc.org/IJCRR.php
with IPAH and secondary PAH (Table 4). 
Clinical outcome after the treatment
After the 6-month Medication treatment, a PAH-related event was 
observed in 12 patients (42.9%), higher than 3 patients (10.8%) 
at 6-month after PADN treatment (p=0.002, Figure 4A); these 
events were mainly driven by the worsening of  PAH (Table 5). 
The mean time from treatment to clinical worsening was 125 days 
(range of  22 to 166 days). After medication treatment, which was 
significantly shorter than the 166 days (range from 47 to 172 days) 
reported after PADN treatment (p=0.01). Re-hospitalization was 
required in 42.9% of  the patients in the Medication compared to 
14.4% of  the patients in the PADN treatment (p=0.018, Table 5). 
There were no peri-PADN procedure access hematomas. Before 
PADN procedure, all patients received CT scanning of  PA. At 
6-month after PADN treatment, CT scanning was performed for 
24 patients, and there were no signs of  aneurysms and thrombus 
formations.
 
At the one-year follow-up, there were 5 (17.9%) PAH-related 
events (2 new events, including 2 sudden deaths). The 6MWD 
in patients without PAH-related events was 467±100 m, which 
was higher than the 393±42 m in patients with PAH-related 
event (p=0.018). When the patients were stratified according to 
6MWD (cut-off  value of  440 m), the rate of  PAH-related events 
in patients with 6MWD ≥ 440m was 7.7%, compared to 26.7% 
(p=0.042, Figure 4B) in patients with 6MWD < 440 m. Of  the 
two deaths (1 CHDSR patient and 1 IPAH patient), the 6MWD 
values at one-year were 303 m and 279 m, even with Δ6MWD of  
82m and 66m, respectively. 
The survival rate-free from PAH-related event at 6-month follow-
up was 88.9% in patients with secondary PH from left heart 
disease after PADN, similar to 89.5% in patients with IPAH and 
secondary PAH (p=0.926, Figure 4C).
Cost analysis
After 6-month Medication treatment, the overall cost 
(35000±12000 USD) was much more expensive than that 
(6000±700 USD, p<0.001) at 6-month after PADN procedure.
Discussion
The major findings of  this study are as follows: [1] PADN, at a 
much lower cost, is safe and is associated with a significant increase 
in 6MWD [2]; the PADN procedure led to a greater improvement 
of  pulmonary arterial hemodynamics with subsequently less 
frequent PAH-related events and re-hospitalizations.
6MWD, Exercise Capacity and Hemodynamics
6MWD has been selected as an endpoint in previous studies for 
PAH patients [13]. Notably, we found that 6MWD improvement 
were negatively associated with the WHO functional class, which 
suggests that a 15% reduction in the 6MWD may be clinically 
meaningful; this result supports the use of  a 15% reduction in 
the 6MWD as a criterion for PAH worsening in clinical studies 
[14, 15].
 
PAP, RAP and PVR were the three most important parameters 
correlated with the prognosis of  the PAH patients [1, 16]. A sPAP 
between 50-70 mmHg and RAP>8 mmHg were markers used 
to indicate the severity of  PAH disease [17]. As a result, a more 
profound reduction of  RAP and PAP was the goal in previous 
Table 4. Comparison of  The Differences of  Measurements at 6-Month After PADN Between IPAH/Secondary PAH And 
PH From Left Heart Disease.
 IPAH/PAH PH 95% CI p
NT-pro BNP, pg/ml -747±1241 -2696±4467 -283.7~4182.4 0.084
WHO functional class, point -0.53±0.51 -0.56±0.73 -0.46~0.52 0.903
6MWD, m 53±72 89±108 -106.7~33.6 0.294
Cardiac output, L/min 0.66±1.20 0.68±0.68 -0.91~-0.86 0.951
RHC
sPAP, mmHg -14.9±16.7 -11.1±5.6 -15.7~8.0 0.511
mPAP, mmHg -8.3±6.7 -6.9±4.8 -6.5~3.8 0.584
PCWP, mmHg 1.1±6.7 -1.2±7.6 -3.5~8.1 0.419
mRAP, mmHg -2.2±3.23 -3.2±4.78 -2.2~4.1 0.524
sRVP, mmHg -12.8±22.2 -13.5±21.1 -7.4~28.9 0.234
PVR, woods unit -5.3±8.4 -3.2±2.7 -7.9~3.9 0.479
Cardiac echo
Pericardial fluid, mm -1.2±2.8 -0.7±1.7 -2.6~1.5 0.596
RV Tei, % -0.33±0.09 -0.35±0.14 -0.07~1.11 0.687
PADN: Pulmonary Artery Denervation; NT-pro BNP: N Terminal-Pro Brain Natriuretic Peptide; 6MWD: 6-Minute Walk Distance; 
RHC: Right Heart Catheterization; sPAP: Systolic Pulmonary Arterial Pressure; mPAP: Mean Pulmonary Arterial Pressure; mRAP: 
Mean Right Atrial Pressure; sRVP: Systolic Right Ventricular (RV)Pressure; PVR: Pulmonary Vessel Resistance.
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Table 5. Clinical Follow-Up After the 6-Month Treatment in 28 Patients.
Medication PADN p
PAH-event, n (%) 12 (42.9) 3 (10.8) 0.002
All-cause death 0 0
Atrial septostomy 0 0
Lung transplantation 0 0
Needing IV & IS 2 (7.2) 0
Worsening of  PAH 10 (36.0) 3 (10.8)
Re-hospitalization, n (%) 12(38.3) 4(14.4) 0.018
Cost, x10,000USD/per pt 3.5±1.2 0.6±0.7 <0.001
Any-cause Death, n (%) 0 0
Access site hematoma, n (%) 0 0
Aneurysm, n (%) 0 0
Thrombus, n (%) 0 0
PADN: Pulmonary Artery Denervation ; PAH: Pulmonary Arterial Hypertension; pt: Patient.
Figure 4A. Rate of  PAH-related event was 42.9% after the 6-month medication treatment, significantly higher than 10.7% at 
the 6-month after PADN procedure (p=0.005). 
Figure 4B. Comparison of  PAH-related event at one-year follow-up between patients with 6-minute walk distance <440 
m (26.7%) and ≥440 m (7.7%, p=0.044) after PADN treatment. PAH, pulmonary arterial hypertension; PADN, pulmonary 
artery denervation. 
Figure 4C. Rate of  PAH-related event in patients with secondary PH from left heart disease was 88.9% at 6-month after 
PADN, similar to 89.5% in patients with IPAH and secondary PAH (p=0.926).
0.0
0.2
0.4
0.6
0.8
1.0
.00 50.00 100.00 150.00 200.00
Days after treatment (d)
C
um
 s
ur
vi
va
l R
at
e 
fr
ee
 f
ro
m
 P
A
H
 r
el
at
ed
 e
ve
n
ts
 (
%
)
Post-Medication, 57.1%
Post-PADN, 89.3%
Log-Rank: p=0.005
A 0.0
0.2
0.4
0.6
0.8
1.0
.00 100.00 200.00 300.00 400.00
Days After PADN Procedure (d)
6MWD<440m, 26.7%
6MWD>=440m, 7.7%
Log-Rank: p=0.044
Cu
m
 su
rv
iv
al 
Ra
te
 fr
ee
 fr
om
 P
A
H
 re
lat
ed
 e
ve
nt
s a
 o
ne
 y
ea
r 
fo
llo
w
up
 (
%
)
0.0
0.2
0.4
0.6
0.8
1.0
.00 50.00 100.00 150.00 200.00
Days after PADN Procedure (d)
PAH, 89.5%
PAH, 88.9%
Log-Rank: p=0.926
C
um
 s
ur
vi
va
l R
at
e 
fr
ee
 f
ro
m
 P
A
H
 r
el
at
ed
 E
ve
n
ts
 (
%
)
Chen SL, Zhang H, Xie DJ, Zhang FF, Zhou L, et al., (2016) Pulmonary Artery Denervation for Treatment of  Pulmonary Arterial Hypertension: Results From a Controlled Before 
and After Study. Int J Cardiol Res. 3(2), 68-77.
76
   OPEN ACCESS                                                                                                                                                                              http://scidoc.org/IJCRR.php
studies [16, 18-20]. We found that the 6MWD improvement after 
the PADN procedure was paralleled by an improvement in RAP, 
sPAP and mPAP. However, we failed to establish a correlation 
between the PA hemodynamics with 6MWD post-medication. 
Consistent with previous report [21], this finding suggest that this 
relationship requires a more significant reduction of  PAP and a 
higher increase of  6MWD, as we found the negative relationship 
between PAP and 6MWD after PADN procedure.
6MWD and clinical outcomes
Some studies [2, 8, 22] with a short-term follow-up reported a 
relationship between baseline 6MWD and clinical events, but 
two meta-analysis studies [13, 23] failed to demonstrate this 
relationship and showed that the absolute 6MWD (≥440m) 
induced by treatment was associated with a lower mortality, 
which was supported by our results showing that patients with 
6MWD≥440m had a lower rate of  PAH-related events. Insight 
analysis into the correlation of  6MWD with clinical outcomes 
based on previous studies [11, 22-24], a short follow-up period, 
and the reduced 6MWD improvement induced by the different 
drugs were three problems that created a lack of  power in the 
conclusions. Savarese et al., [3] showed that in patients with PAH, 
an improvement in 6MWD did not reflect a benefit in clinical 
results. The reason for this discrepancy may be the overall shorter 
clinical follow-up period (a median of  14.5 weeks) and the 34 
m of  Δ6MWD, compared to the 6-month follow-up and 65 m 
reduction in 6MWD by our study. Of  the three studies (using 
tadanafil with different dosages, imatinib and aspirin) with 24-26 
weeks of  follow-up [18-20], there was only an average 6MWD 
improvement of  8 m in the medication group, which was similar 
to the 4 m improvement in the control group. These results are all 
significantly lower than our findings, which reflect the significant 
improvement achieved by the PADN procedure.
Clinical Relevance
The PADN procedure was adapted from previous animal studies 
[6, 7] and was first used in humans in our study [8]. PADN-1 
reported a mean 6MWD improvement of  100 m at 3-months 
follow-up after the PADN procedure [8], and the current study 
showed 6-month changes in the 6MWD of  65 m and a change 
of  92 m at one-year after the denervation. Because the PADN 
procedure was associated with a more significant increase in 
6MWD paralleled with the reduction of  sPAP and mPAP, and 
a lower rate of  PAH-related events and lower cost compared to 
previous clinical studies using different drugs [13], demonstrated 
the clinical importance of  PADN for PAH patients.
Limitations
One major limitation of  the current study is the study design. To 
compensate for this limitation, the control implemented before 
and after the design support the relevance of  the significant 
improvement shown in 6MWD after PADN compared to using 
medications. The results confirmed our findings in the PADN-
1 study [8]. A second limitation is the small sample size in this 
study, which may not yield results that is generalizable to the 
general population. Interestingly, we found that when follow-
up was extended to one-year, not only was 6MWD continuously 
negatively correlated with exercise capacity but also predicted 
the occurrence of  PAH-related events. Furthermore, our results 
showed that a 6MWD of  a minimum of  400 m might be a good 
parameter to predict patients’ prognosis. Alternatively, this study 
was conducted at two centers; therefore, a learning curve for 
PADN should be completed when this procedure is used in other 
centers. Due to small patient size, we did not perform further 
comparison between PAH with PH induced by LHD. Lastly, the 
present study included PAH patients with different etiologies. As 
a result, our preliminary results should be translated into clinical 
practice with caution.
Conclusion
This controlled before and after study showed the improvement 
of  6MWD and its correlation with exercise capacity and clinical 
outcomes after the PADN procedure. Further randomized studies 
with larger patient samples are required to show the benefits of  
PADN for PAH patients.
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